Advancements in dendritic cell vaccination: enhancing efficacy and optimizing combinatorial strategies for the treatment of glioblastoma

被引:2
|
作者
Subtirelu, Robert C. [1 ]
Teichner, Eric M. [2 ]
Ashok, Arjun [2 ]
Parikh, Chitra [2 ]
Talasila, Sahithi [2 ]
Matache, Irina-Mihaela [3 ]
Alnemri, Ahab G. [1 ]
Anderson, Victoria [2 ]
Shahid, Osmaan [1 ]
Mannam, Sricharvi [1 ]
Lee, Andrew [1 ]
Werner, Thomas [1 ]
Revheim, Mona-Elisabeth [4 ,5 ]
Alavi, Abass [1 ]
机构
[1] Hosp Univ Penn, Dept Radiol, Philadelphia, PA USA
[2] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA USA
[3] Carol Davila Univ Med & Pharm, Dept Physiol, Fac Med, Bucharest, Romania
[4] Oslo Univ Hosp, Div Orthoped Surg, Oslo, Norway
[5] Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway
来源
FRONTIERS IN NEUROLOGY | 2023年 / 14卷
关键词
glioblastoma; dendritic cell vaccination; positron emission tomography; antigen loading; immunotherapy; CYTOTOXIC T-LYMPHOCYTES; MALIGNANT GLIOMA; TUMOR-ANTIGEN; BRAIN-TUMOR; FDG-PET; MULTIFORME; VACCINES; IMMUNOTHERAPY; RESPONSES; SURVIVAL;
D O I
10.3389/fneur.2023.1271822
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Glioblastomas (GBM) are highly invasive, malignant primary brain tumors. The overall prognosis is poor, and management of GBMs remains a formidable challenge, necessitating novel therapeutic strategies such as dendritic cell vaccinations (DCVs). While many early clinical trials demonstrate an induction of an antitumoral immune response, outcomes are mixed and dependent on numerous factors that vary between trials. Optimization of DCVs is essential; the selection of GBM-specific antigens and the utilization of 18F-fludeoxyglucose Positron Emission Tomography (FDG-PET) may add significant value and ultimately improve outcomes for patients undergoing treatment for glioblastoma. This review provides an overview of the mechanism of DCV, assesses previous clinical trials, and discusses future strategies for the integration of DCV into glioblastoma treatment protocols. To conclude, the review discusses challenges associated with the use of DCVs and highlights the potential of integrating DCV with standard therapies.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Advances and challenges: dendritic cell vaccination strategies for glioblastoma
    Schaller, Teilo H.
    Sampson, John H.
    EXPERT REVIEW OF VACCINES, 2017, 16 (01) : 27 - 36
  • [2] Empowering dendritic cell cancer vaccination: the role of combinatorial strategies
    Galati, Domenico
    Zanotta, Serena
    CYTOTHERAPY, 2018, 20 (11) : 1309 - 1323
  • [3] Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma
    Batich, Kristen A.
    Swartz, Adam M.
    Sampson, John H.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (01) : 79 - 94
  • [4] Dendritic cell vaccination and amplification strategies
    Schuler, Gerold
    ANNALS OF ONCOLOGY, 2006, 17 : 41 - 41
  • [5] A Comparative Study of the Intratumor Immune Effect of DendritIc Cell Vaccination and the Conventional Treatment in Glioblastoma
    Idoate, Miguel
    Arana, Inigo
    Diez-Valle, Ricardo
    Inoges, Susana
    Lopez, Ascension
    Echeveste, Jose
    Lozano, Maria
    Tejada, Sonia
    Guillen Grima, Francisco
    LABORATORY INVESTIGATION, 2015, 95 : 431A - 431A
  • [6] Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response
    Dejaegher, Joost
    Van Gool, Stefaan
    De Vleeschouwer, Steven
    IMMUNOTARGETS AND THERAPY, 2014, 3 : 55 - 66
  • [7] A Comparative Study of the Intratumor Immune Effect of Dendritic Cell Vaccination and the Conventional Treatment in Glioblastoma
    Idoate, Miguel
    Arana, Inigo
    Diez-Valle, Ricardo
    Inoges, Susana
    Lopez, Ascension
    Echeveste, Jose
    Lozano, Maria
    Tejada, Sonia
    Guillen Grima, Francisco
    MODERN PATHOLOGY, 2015, 28 : 431A - 431A
  • [8] CYTOTOXIC T CELL FUNCTIONAL RESPONSIVENESS MAY PREDICT CLINICAL EFFICACY OF DENDRITIC CELL VACCINATION IN GLIOBLASTOMA PATIENTS
    Everson, Richard
    Jin, Richard
    Safaee, Michael
    Lisiero, Dominique
    Odesa, Sylvia
    Liau, Linda
    Prins, Robert
    NEURO-ONCOLOGY, 2013, 15 : 69 - 69
  • [9] Boosting Dendritic Cell Vaccination for Glioblastoma Using Tetanus Toxoid
    Sonabend, Adam M.
    McKhann, Guy M.
    NEUROSURGERY, 2015, 77 (02) : N20 - N21
  • [10] Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End
    Datsi, Angeliki
    Sorg, Ruediger V.
    FRONTIERS IN IMMUNOLOGY, 2021, 12